The EVOKE and EVOKE+ research programmes tested an oral version of semaglutide the same substance used in the popular Ozempic/Wegovy injections but found it failed to slow disease progression in patients with early Alzheimers disease.i On December 1, 2025, Imperial led a trial using liraglutide a drug from the same GLP-1 class produced surprisingly promising results: nearly 50% less brain volume loss and an 18% slower decline in cognitive function.ii These promising results were published in Nature.iii So, what can we learn from these contrasting findings
The Glow peptide blend positions these three mechanisms within a single preparation: vascular support via BPC-157, cellular motility and structural repair via TB-500, and matrix remodeling with antioxidant activity via GHK-Cu
H.KimN.KimD
Signaling of extracellular matrix structure
Semaglutide is a safe and effective treatment for weight loss, however, it is rare, Semaglutide has shown some more severe side effects during testing, including: Allergic reactions (including swelling of the face, tongue, or throat
I've seen it work when other treatments stalled